Table 3. Selected Biocarta pathways which were significantly differentially expressed between BV6- and DMSO-treated samples (BV6-sensitive cases).

Biocarta Pathway	Pathway description	# of genes	LS p-value	KS p-value	Efron-Tibshirani's p-value
h DNAfragment Pathway	Apoptotic DNA fragmentation and tissue homeostasis	15	0.00003	0.04441	< 0.005
h smP athway	Spliceosomal Assembly	22	0.00003	0.04504	< 0.005
h il18 Pathway	IL 18 Signaling Pathway	7	0.00136	0.00337	< 0.005
h rab Pathway	Rab GTPases Mark Targets In The Endocytotic Machinery	25	0.00242	0.04861	< 0.005
h tnfr1 Pathway	TNFR1 Signaling Pathway	37	0.0038	0.00918	< 0.005
h cpsf Pathway	Polyadenylation of mRNA	9	0.00931	0.01273	< 0.005
h eif2 Pathway	Regulation of eIF2	18	0.01638	0.01819	< 0.005
h d4gdi Pathway	D4-GDI Signaling Pathway	21	0.02449	0.28193	< 0.005
h RacCycD Pathway	Influence of Ras and Rho proteins on G1 to S Transition	34	0.02801	0.05138	< 0.005
h prc2 Pathway	The PRC2 Complex Sets Long-term Gene Silencing Through Modification of Histone Tails	13	0.03252	0.10773	< 0.005
h bard1 Pathway	BRCA1-dependent Ub-ligase activity	5	0.04497	0.08486	< 0.005
h caspase Pathway	Caspase Cascade in Apoptosis	36	0.04637	0.51603	< 0.005
h aif Pathway	Opposing roles of AIF in Apoptosis and Cell Survival	5	0.29515	0.46769	< 0.005
h NF-κB Pathway	NF-κB Signaling Pathway	25	0.42002	0.08742	< 0.005

In total, 60 Biocarta pathways were differentially regulated specifically in BV6-sensitive cases (BV6 vs. DMSO treatment). Here we show an excerpt of 12 Biocarta pathways (P <.05 in LS/KS test), plus two others that were especially relevant.